Pennsylvania Trust Co reduced its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 61.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,424 shares of the pharmaceutical company’s stock after selling 15,276 shares during the period. Pennsylvania Trust Co’s holdings in GlaxoSmithKline were worth $958,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Fisher Asset Management LLC increased its stake in shares of GlaxoSmithKline by 0.7% during the fourth quarter. Fisher Asset Management LLC now owns 14,102,560 shares of the pharmaceutical company’s stock worth $538,859,000 after purchasing an additional 91,232 shares in the last quarter. Morgan Stanley increased its stake in shares of GlaxoSmithKline by 16.5% during the third quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock worth $169,232,000 after purchasing an additional 597,367 shares in the last quarter. Macquarie Group Ltd. increased its stake in shares of GlaxoSmithKline by 0.4% during the fourth quarter. Macquarie Group Ltd. now owns 2,536,432 shares of the pharmaceutical company’s stock worth $96,917,000 after purchasing an additional 9,642 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of GlaxoSmithKline by 1,788.6% during the third quarter. Bank of New York Mellon Corp now owns 2,306,091 shares of the pharmaceutical company’s stock worth $92,636,000 after purchasing an additional 2,183,983 shares in the last quarter. Finally, Eaton Vance Management increased its stake in shares of GlaxoSmithKline by 1.6% during the fourth quarter. Eaton Vance Management now owns 1,947,128 shares of the pharmaceutical company’s stock worth $74,400,000 after purchasing an additional 30,357 shares in the last quarter. Institutional investors and hedge funds own 11.08% of the company’s stock.

A number of analysts have recently commented on the stock. Shore Capital cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Zacks Investment Research raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Exane BNP Paribas cut shares of GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research note on Monday, January 14th. BNP Paribas cut shares of GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research note on Monday, January 14th. Finally, UBS Group cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $41.99.

Shares of NYSE GSK opened at $39.85 on Friday. GlaxoSmithKline plc has a 12-month low of $36.41 and a 12-month high of $42.36. The stock has a market cap of $98.85 billion, a P/E ratio of 12.61, a price-to-earnings-growth ratio of 1.99 and a beta of 0.76. The company has a debt-to-equity ratio of 5.52, a current ratio of 0.75 and a quick ratio of 0.51.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. The company had revenue of $10.55 billion during the quarter, compared to analysts’ expectations of $9.85 billion. As a group, equities analysts forecast that GlaxoSmithKline plc will post 2.91 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 22nd were paid a dividend of $0.597 per share. This represents a $2.39 annualized dividend and a yield of 5.99%. The ex-dividend date of this dividend was Thursday, February 21st. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is currently 75.32%.

COPYRIGHT VIOLATION NOTICE: “Pennsylvania Trust Co Lowers Stake in GlaxoSmithKline plc (GSK)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/pennsylvania-trust-co-lowers-stake-in-glaxosmithkline-plc-gsk/2979368.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.